44 charts that explain markets and the economy right now

NasdaqGM - Nasdaq Real Time Price USD

Arcturus Therapeutics Holdings Inc. (ARCT)

Compare

16.97

-0.45

(-2.58%)

At close: January 31 at 4:00:01 PM EST

17.49

+0.52

+(3.06%)

After hours: January 31 at 6:40:11 PM EST

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

TOKYO, January 31, 2025--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of "KOSTAIVE® for Intramuscular Injection," a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan.

Business Wire yesterday

ARCT
-2.58%
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

SAN DIEGO, January 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time.

Business Wire yesterday

ARCT
-2.58%
Arcturus Therapeutics launches Phase I Avian Influenza trials in US

The announcement follows just days after the US Centres for Disease Control confirmed its first death from the zoonotic disease.

Clinical Trials Arena 21 days ago

ARCT
-2.58%
GLDAF
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

SAN DIEGO, January 10, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H

Business Wire 22 days ago

ARCT
-2.58%
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, January 06, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company’s Phase 2 multiple ascending dose studies.

Business Wire 25 days ago

ARCT
-2.58%
High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others

Over the last 7 days, the United States market has experienced a 2.2% drop, yet it is up 24% over the past year with earnings forecast to grow by 15% annually. In this context of fluctuating yet promising growth, identifying high-growth tech stocks such as Arcturus Therapeutics Holdings requires an understanding of their potential to capitalize on technological advancements and market opportunities amidst these dynamic conditions.

Simply Wall St. last month

GLOB

RPD

ARCT
-2.58%
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. last month

ARCT
-2.58%
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, December 16, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time.

Business Wire last month

ARCT
-2.58%
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known […]

Insider Monkey last month

ARCT
-2.58%
Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO, November 26, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:

Business Wire 2 months ago

ARCT
-2.58%
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

SAN DIEGO, November 19, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.

Business Wire 2 months ago

ARCT
-2.58%
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

TOKYO, November 14, 2024--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS").

Business Wire 2 months ago

ARCT
-2.58%
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

SAN DIEGO, November 11, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a "Study Can Proceed" notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine c

Business Wire 2 months ago

ARCT
-2.58%
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations

Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Third Quarter 2024 Results Key Financial Results Revenue: US$41.7m (down...

Simply Wall St. 2 months ago

ARCT
-2.58%
Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

ARCT
-2.58%
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...

Despite a dip in revenue, Arcturus Therapeutics Holdings Inc (ARCT) celebrates a successful vaccine launch in Japan and strong financial positioning.

GuruFocus.com 2 months ago

ARCT
-2.58%
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 62.86% and 15.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ARCT
-2.58%
Arcturus Therapeutics: Q3 Earnings Snapshot

SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $6.9 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 26 cents. The results beat Wall Street expectations.

Associated Press Finance 2 months ago

ARCT
-2.58%
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

SAN DIEGO, November 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates.

Business Wire 2 months ago

ARCT
-2.58%
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.

Zacks 2 months ago

ARCT
-2.58%

Performance Overview

Return	ARCT	S&P 500
YTD	+2.35%	+2.26%
1-Year	-48.10%	+22.65%
3-Year	-23.90%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arcturus Therapeutics Holdings Inc. (ARCT)

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Arcturus Therapeutics launches Phase I Avian Influenza trials in US

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others

We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Arcturus Therapeutics: Q3 Earnings Snapshot

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

Performance Overview